Creating new businesses through collaboration with and investment in other companies
First written in FY2019. 4 of 9 entries say "Advanced", first in FY2021. Latest entry: FY2026.
93 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「We will consider establishing a new U.S. company for healthcare-related businesses while strengthening the development of medical and pharmaceutical-related products.」
The company is advancing its collaboration with other companies and efforts to create new businesses by considering the establishment of a new US healthcare company and strengthening the rollout of medical and pharmaceutical products. - FY2025AdvancedAnnual report
「In addition to granting KAKEN PHARMACEUTICAL CO.,LTD. exclusive sales rights for the new wound-healing material, “Silk Elastin® Wound Sheet,” we are focusing on efforts to commercialise several new businesses in areas including food and healthcare, centred on carbon neutrality and improving QOL (quality of life), and progress toward monetisation is broadly in line with expectations.」
The company has given concrete form to collaboration and technology transfer with other companies by granting exclusive sales rights for the silk-elastin wound-healing material and commercialising new businesses in the food and healthcare fields. - FY2025-H1AdvancedAnnual report
「Technology transfer contract: Contracting company: SANYO CHEMICAL INDUSTRIES,LTD.; counterparty: KAKEN PHARMACEUTICAL CO.,LTD.; contracted product: wound-healing material using silk elastin; details: arrangements for the licensing of patents, know-how and trademarks required to manufacture and market this medical device in Japan, in connection with the commercialisation of a wound-healing material using silk elastin; contract date: 26 September 2024」
For a wound-healing material using silk elastin, the company entered into a technology transfer agreement with KAKEN PHARMACEUTICAL CO.,LTD. and has moved to the licensing stage for patents, know-how and trademarks ahead of commercialisation in Japan. - FY2023Update to alliance partners and investment structureAnnual report
「富士フイルム三洋化成ヘルスケア㈱ was established through a joint investment with 富士フイルム㈱. As part of the shares of ＡＰＢ株式会社 was sold, reducing the ownership interest in the company, APB was excluded from the scope of application of the equity method.」
In the healthcare field, the company established a jointly invested company with 富士フイルム, while APB was excluded from the scope of application of the equity method following the sale of part of its shares. - FY2023-Q3Exclusion from the Equity-Method ScopeAnnual report
「During the consolidated accounting period for the third quarter, ＡＰＢ株式会社 was excluded from the scope of application of the equity method because part of its shares was sold, reducing the ownership interest in the company.」
The company states that APB's ownership interest declined following the sale of part of its shares, and that APB was excluded from the scope of application of the equity method. - FY2021AdvancedAnnual report
「We have worked to enhance corporate value in a way that contributes to a sustainable society by developing an all-resin battery with our equity-method affiliate ＡＰＢ㈱, promoting large-scale new businesses in the biomedical, agrinutrition and cosmetics fields, forming alliances with external companies, exemplified by capital partnerships with 株式会社TBM, ティエムファクトリ株式会社 and 株式会社ファーマフーズ, and accelerating globalisation through investment in new and expanded facilities in Thailand, South Korea and elsewhere.」
The company has specified collaboration and capital partnerships with APB, TBM, ティエムファクトリ and ファーマフーズ as concrete achievements in advancing new businesses and technology development. - FY2019First statedAnnual report
「Going forward, we will actively pursue collaboration with other companies in areas expected to expand. In the bio and medical fields, we will invest in Delta-Fly-Pharma㈱ and pursue joint research into new anticancer drugs. In the energy and electronics fields, we will invest in ＡＰＢ㈱, a technology venture developing lithium-ion batteries, and pursue the development of new lithium-ion batteries. Outside the new-business fields, we will invest in ㈱ＴＢＭ, which manufactures products using limestone that is attracting attention as an alternative to paper and plastic, and apply our technologies to its products to address growing social demand for reduced environmental impact.」
For new businesses and environmental-impact reduction, the company is presenting for the first time a systematic approach involving investment in Delta-Fly-Pharma, APB and TBM, together with joint research and technology applications.